Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX7 | Q99572 | 3/20 | 0.41 |
| ▸ | OPRM1 | P35372 | 4/20 | 0.38 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.37 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.36 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.36 |
| ▸ | IDO1 | P14902 | 1/20 | 0.36 |
| ▸ | TDO2 | P48775 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | OPRL1 | P41146 | 2/20 | 0.35 |
| ▸ | MCOLN1 | Q9GZU1 | 1/20 | 0.35 |
| ▸ | CCR2 | P41597 | 1/20 | 0.34 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4890954 | 0.93 | P2RX7 (0.40) | P2RX7OPRM1FFAR1HDAC1HDAC6 | |
| SCHEMBL4890619 | 0.91 | NOTUM (0.44) | P2RX7HDAC1HDAC6MCOLN1NOTUM | |
| SCHEMBL4888879 | 0.91 | OPRM1 (0.41) | OPRM1FFAR1HDAC1HDAC6IDO1 | |
| SCHEMBL4888898 | 0.87 | OPRM1 (0.39) | OPRM1FFAR1HDAC1HDAC6KMT2A | |
| SCHEMBL4889960 | 0.84 | OPRM1 (0.41) | OPRM1FFAR1HDAC1HDAC6IDO1 | |
| SCHEMBL4893344 | 0.84 | OPRM1 (0.41) | OPRM1FFAR1HDAC1HDAC6OPRL1 | |
| SCHEMBL4886704 | 0.84 | NOTUM (0.38) | OPRM1FFAR1HDAC1HDAC6OPRL1 | |
| SCHEMBL4889940 | 0.82 | NOTUM (0.47) | OPRM1HDAC1HDAC6NOTUM | |
| SCHEMBL4890886 | 0.80 | ATM (0.36) | OPRM1FFAR1HDAC1HDAC6NOTUM | |
| SCHEMBL4893188 | 0.80 | NOTUM (0.43) | P2RX7HDAC1HDAC6NOTUM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080200491-A1 | 1,2-Dihydro-Spiro[3H-Indole-3,4'-Piperidine] Compounds, as Modulators of the Mas Receptor Novel | ARENA PHARMACEUTICALS, INC. | 2008-08-21 | — | — | US | claimed |
| US-20080200491-A1 | 1,2-Dihydro-Spiro[3H-Indole-3,4'-Piperidine] Compounds, as Modulators of the Mas Receptor Novel | ARENA PHARMACEUTICALS, INC. | 2008-08-21 | — | — | US | disclosed |
| US-20080200491-A1 | 1,2-Dihydro-Spiro[3H-Indole-3,4'-Piperidine] Compounds, as Modulators of the Mas Receptor Novel | ARENA PHARMACEUTICALS, INC. | 2008-08-21 | — | — | US | disclosed |
| US-20080200491-A1 | 1,2-Dihydro-Spiro[3H-Indole-3,4'-Piperidine] Compounds, as Modulators of the Mas Receptor Novel | ARENA PHARMACEUTICALS, INC. | 2008-08-21 | — | — | US | disclosed |
| WO-2007002114-A1 | 1,2-DIHYDRO-SPIRO(3H-INDOLE-3-4’-PIPERIDINE) COMPOUNDS AS MODULATORS OF THE MAS RECEPTOR NOVEL | ARENA PHARMACEUTICALS, INC. (US) | 2007-01-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080200491-A1 | 1,2-Dihydro-Spiro[3H-Indole-3,4'-Piperidine] Compounds, as Modulators of the Mas Receptor Novel | AGTR1, AGTR2, AVPR2 | P2RX7 427/4885OPRM1 343/4885FFAR1 166/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.